Press and Publications You will find in this section all the publications and press releases produced by the MIROCALS consortium. This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 633413. Gilbert BensimonGilbert is a biotechnologist specializing in the human microbiome, whose research has contributed to …
Neuroimaging delves deeper into brain changes in ALS A group of people with ALS taking part in MIROCALS have generously agreed to also participate in an additional study at Brighton and Sussex Medical School. The ANNALS-QuICT (Analysing Neuroinflammation in Neurodegeneration in Amyotrophic Lateral Sclerosis) study uses Magnetic Resonance Imaging (MRI) scanning to look for changes …
Charities and Patient Associations rally around MIROCALS to show their support Clinical trials are expensive to run and with several more neurology clinics taking part, it has created an additional challenge by increasing the cost of running the trial beyond the original generous grants from the European Commission and the French Health Ministry. Professor Nigel …
End of trial recruitment phase this autumn The MIROCALS (Modifying Immune Response and Outcomes in ALS) Clinical Trial is still on-going, with recruitment continuing until the end of September 2019. The MIROCALS trial is testing whether low doses of the drug Interleukin-2 (IL-2) can alter aspects of the immune system, which may play a role …
Workprogramme PERT diagram (Click to zoom) MIROCALS aims to perform a novel intervention study with the potential to: halt disease progression test the proof of concept that biomarkers can accelerate future intervention studies provide unique insights on disease pathogenesis identifying novel targets for intervention. The workprogramme has been structured in 7 workpackages (WPs): WP2 and …
Project partners MIROCALS consortium is formed by 12 organisations in the EU to conduct a phase II Proof of Concept / Proof of Mechanism Clinical Trial aiming to test the interleukin-2 (IL-2) as treatment for amyotrophic lateral sclerosis (ALS). The science of the project is coordinated by Dr Gilbert Bensimon of the University Hospital of …